NuCana plc (NCNA)

Market Cap	32.49M
Revenue (ttm)	n/a
Net Income (ttm)	-41.78M
Shares Out	52.40M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,960
Open	0.620
Previous Close	0.620
Day's Range	0.602 - 0.640
52-Week Range	0.590 - 1.750
Beta	1.16
Analysts	Strong Buy
Price Target	4.33 (+598.39%)
Earnings Date	Nov 15, 2023

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 28, 2017
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: NCNA

Financial Performance

Financial numbers in GBP

Analyst Forecast

According to 3 analysts, the average rating for NCNA stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 598.39% from the latest price.

Price Target

$4.33

(598.39% upside)

Analyst Consensus: Strong Buy